





## APPENDIX TO AMENDMENT OF APRIL 2, 2001

### Amendments to the Claims

1. (Twice Amended) A method for increasing the tolerance of a mammal to transgenic cells, after discontinuing concomitant immunosuppressant therapy, by administering a pharmaceutical [or pharmaceutical combination] comprising p15-deoxyspergualin, anti-T-cell antibody, corticosteriod, azathioprine, or methotrexate[ or a compound of the formula (I) or (II)



or an optionally stereoisomeric form of the compound of the formula I or II and/or a physiologically tolerable salt of the compound of the formula I wherein:

- $\text{R}^1$  is
- a)  $(\text{C}_1-\text{C}_4)$ -alkyl,
  - b)  $(\text{C}_3-\text{C}_5)$ -cycloalkyl,
  - c)  $(\text{C}_2-\text{C}_6)$ -alkenyl or
  - d)  $(\text{C}_2-\text{C}_6)$ -alkynyl,

- $R^2$  is
- a)  $-CF_3$ ,
  - b)  $-O-CF_3$ ,
  - c)  $-S-CF_3$ ,
  - d)  $-OH$ ,
  - e)  $-NO_2$ ,
  - f) halogen,
  - g) benzyl,
  - h) phenyl,
  - i)  $-O$ -phenyl,
  - k)  $-CN$  or

$-O$ -phenyl, mono- or polysubstituted by

- 1)  $(C_1-C_4)$ -alkyl,
- 2) halogen,
- 3)  $-O-CF_3$  or
- 4)  $-O-CH_3$ ,

- $R^3$  is
- a)  $(C_1-C_4)$ -alkyl,
  - b) halogen, or
  - c) a hydrogen atom, and

- X is
- a) a  $-CH$  group or
  - b) a nitrogen atom].

4. (Twice Amended) The method as claimed in claim 1, wherein the pharmaceutical [or the pharmaceutical combination] is administered before, during

and/or after the administration of the transgenic cells produced in vitro or [in-vivo] in vivo.

9. (Twice Amended) The method as claimed in claim 1, wherein the pharmaceutical [or the pharmaceutical combination] is administered orally, intravenously, subcutaneously, intraperitoneally, percutaneously, cutaneously, topically, by inhalation, intramuscularly, intrathecally, intraocularly, ocularly, buccally, nasally, or rectally.

10. (Amended) The method as claimed in claim 9, wherein the pharmaceutical [or the pharmaceutical combination] is administered orally or intravenously.

B<sup>1</sup>  
administering a pharmaceutical comprising p15-deoxyspergualin, anti-T-cell antibody, corticosteriod, azathioprine, or methotrexate.

B<sup>2</sup>  
4. (Twice Amended) The method as claimed in claim 1, wherein the pharmaceutical is administered before, during and/or after the administration of the transgenic cells produced in vitro or in vivo.

B<sup>3</sup>  
9. (Twice Amended) The method as claimed in claim 1, wherein the pharmaceutical is administered orally, intravenously, subcutaneously, intraperitoneally, percutaneously, cutaneously, topically, by inhalation, intramuscularly, intrathecally, intraocularly, ocularly, buccally, nasally, or rectally.

B<sup>4</sup>  
10. (Amended) The method as claimed in claim 9, wherein the pharmaceutical is administered orally or intravenously.

**REMARKS**

Claims 1 and 4-15 are currently pending in this application. Claims 2 and 3 have been cancelled without prejudice or disclaimer, and claims 1, 4, 9, and 10 have been amended. Support for these amendments can be found in the specification as a whole. These amendments raise no issue of new matter and Applicants respectfully request their entry.